Rolling its valuation models to year‑end 2026, Wolfe raised its fair‑value range to $53–$112 a share, compared with Monday’s $69 close, and said the risk‑reward now tilts positive even though downside ...

Symvess, described as an acellular tissue engineered vessel, received FDA approval for extremity vascular trauma indication in December 2024. The product is part of Humacyte’s commercial-stage ...

Investing.com -- Recursion Pharmaceuticals Inc (NASDAQ: RXRX) stock surged 11.5% while Rallybio Corp (NASDAQ: RLYB) shares ...